Status:
COMPLETED
Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coronary Syndrome: The ZESCA Trial
Lead Sponsor:
Mark Eisenberg
Collaborating Sponsors:
Canadian Institutes of Health Research (CIHR)
Heart and Stroke Foundation of Canada
Conditions:
Acute Coronary Syndrome
Myocardial Infarction
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Patients who continue to smoke after a heart attack have a 35% increased risk of a recurrent event or death compared with those who quit. Many patients attempt to stop smoking after a heart attack, bu...
Detailed Description
Patients who continue smoking after ACS have a 35% increased risk of reinfarction or death compared with those who quit. Many patients attempt to stop smoking after an acute coronary syndrome (ACS), b...
Eligibility Criteria
Inclusion
- ≥ 18 years of age
- Smoke at least 10 cigarettes/day for the past year
- Suffered an enzyme-positive ACS
- Planned hospitalization of ≥24 hours
- Motivated to quit smoking
- Likely to be available for follow-up
- Able to understand and read English or French
Exclusion
- Medical condition with a prognosis of \< 1 year
- Pregnant or lactating
- Current use of Wellbutrin or any other medications that contain bupropion
- Current use of any medical therapy for smoking cessation (e.g. BuSpar, fluoxetine, doxepin, nicotine gum, or nicotine patch)
- Current seizure disorder, history of seizures or predisposition to seizures (e.g. history of brain tumor, severe head trauma, or stroke)
- History of bulimia or anorexia nervosa
- Current diagnosis of major depression (requiring medication), bipolar disease, or dementia
- History of suicidal events (previous suicide attempt, suicidal ideation) or family history of suicide
- Diagnosed hepatic failure, cirrhosis, hepatitis or history of hepatic impairment (AST or ALT levels ≥ 2 times upper limit of normal prior to admission for ACS)
- Renal impairment with creatinine levels ≥ 2 times the upper limit of normal
- Excessive alcohol consumption defined as ≥ 14 alcoholic drinks per week
- Use of any illegal drugs in the past year (e.g. cocaine, heroin, opiates)
- Current use of medications that lower seizure threshold e.g. amantadine, anti-depressants, anti-malarials, anti-psychotics, levodopa, lithium, quinolone antibiotics, ritonavir, systemic steroids, theophyllin, type 1C antiarrhythmics (e.g. encainide, flecainide, propafenone)
- Use of MAO inhibitors or thioridazine in the past 15 days
- Current use of over-the-counter stimulants (e.g. ephedrine, phenylephrine) or anoretics
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
392 Patients enrolled
Trial Details
Trial ID
NCT00689611
Start Date
December 1 2005
End Date
June 1 2010
Last Update
April 23 2015
Active Locations (38)
Enter a location and click search to find clinical trials sorted by distance.
1
Parkview Medcial Center
Pueblo, Colorado, United States, 81003
2
Central Maine Medical Center
Lewiston, Maine, United States, 04240
3
Bay Regional Medical Center
Bay City, Michigan, United States
4
Bassett Healthcare
Cooperstown, New York, United States, 13326